Drug combo aims to boost lung cancer treatment

NCT ID NCT03392246

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This phase 2 study tests whether combining two targeted drugs, osimertinib and selumetinib, can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer who have not yet received EGFR inhibitors. The trial enrolls 25 participants and measures how well the tumors respond and how long progression is delayed. The goal is to see if the combination works better than osimertinib alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: osimertinib (Tagrisso) and selumetinib
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced EGFR-mutant lung cancer, potentially improving tumor shrinkage and delaying progression.
What could go wrong: This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The combination may cause more side effects than osimertinib alone, and it's not yet clear if it works better than standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke University

Durham, North Carolina, 27710, United States
Massachusetts General Hospital

Boston, Massachusetts, 02214, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.